Inhibition of PDGF-BB-induced PDGFRbeta activation in human SH-SY5Y cells pretreated for 60 mins followed by PDGF-BB addition and measured after 10 mins by ELISA
Antitumor activity against human A498 cells xenografted in athymic nude mouse assessed as reduction in tumor volume at 25 mg/kg, ip qd for 19 days measured post last dose up to 40 days
Antitumor activity against human A498 cells xenografted in athymic nude mouse assessed as reduction in tumor volume at 25 mg/kg, ip q2d for 19 days measured post last dose up to 40 days
Antitumor activity against human A498 cells xenografted in athymic nude mouse assessed as reduction in tumor volume at 25 mg/kg, ip q3d for 19 days measured post last dose up to 40 days
Toxicity in athymic nude mouse xenografted with human A498 cells assessed as body weight at 25 mg/kg, ip qd for 19 days measured post last dose relative to control
Toxicity in athymic nude mouse xenografted with human A498 cells assessed as body weight at 25 mg/kg, ip q2d for 19 days measured post last dose relative to control
Toxicity in athymic nude mouse xenografted with human A498 cells assessed as body weight at 25 mg/kg, ip q3d for 19 days measured post last dose relative to control
Antitumor activity against human NCI-H23 cells xenografted in sc dosed mouse assessed as reduction in cell viability administered daily for 4 days starting from 3 to 4 days post implantation measured post last dose by MTT based in-vivo hollow fiber assay
Antitumor activity against human NCI-H522 cells xenografted in sc dosed mouse assessed as reduction in cell viability administered daily for 4 days starting from 3 to 4 days post implantation measured post last dose by MTT based in-vivo hollow fiber assay